Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VS-6766 + everolimus
- Development stage
- Phase 1
- Lead developer
- Verastem Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VS-6766 is a small molecule RAF/MEK clamp that reduces p-MEK and p-ERK, while everolimus is an mTOR inhibitor. The combination of VS-6766 and everolimus has shown preclinical synergy in KRAS-mutant non-small cell lung cancer (NSCLC) cell lines. This drug combination aims to simultaneously block two key pathways (RAF/MEK and mTOR) that KRAS-driven cancers rely on for growth, potentially delaying the development of resistance. Clinical trials have evaluated intermittent dosing schedules for safety and efficacy, with promising early results in patients with KRAS-mutant NSCLC who have exhausted other treatment options.
- Other names
- RAF/MEK clamp VS-6766 plus everolimusVS-6766 and everolimus combinationVS6766 and everolimus combinationVS 6766 and everolimus combination
02
Targets
Mechanistic target of rapamycin complex 1MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)RAF1 (c-Raf-1 (Y340D/Y341D))Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on VS-6766 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VS-6766 + everolimus.